WO2007115175A3 - Cyclic natriuretic peptide constructs - Google Patents

Cyclic natriuretic peptide constructs Download PDF

Info

Publication number
WO2007115175A3
WO2007115175A3 PCT/US2007/065645 US2007065645W WO2007115175A3 WO 2007115175 A3 WO2007115175 A3 WO 2007115175A3 US 2007065645 W US2007065645 W US 2007065645W WO 2007115175 A3 WO2007115175 A3 WO 2007115175A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic peptide
cyclic
peptide constructs
terminus
amino acid
Prior art date
Application number
PCT/US2007/065645
Other languages
French (fr)
Other versions
WO2007115175A2 (en
Inventor
Shubh D Sharama
Margarita Bastos
Wei Yang
Hui-Zhi Cai
Original Assignee
Palatin Technologies Inc
Shubh D Sharama
Margarita Bastos
Wei Yang
Hui-Zhi Cai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020087026715A priority Critical patent/KR101434612B1/en
Priority to MX2008012663A priority patent/MX2008012663A/en
Priority to CN200780019541.7A priority patent/CN101505784B/en
Priority to JP2009503312A priority patent/JP5355383B2/en
Priority to EA200802059A priority patent/EA016804B1/en
Priority to AU2007233116A priority patent/AU2007233116B2/en
Priority to ES07759833T priority patent/ES2430323T3/en
Priority to CA002647143A priority patent/CA2647143A1/en
Application filed by Palatin Technologies Inc, Shubh D Sharama, Margarita Bastos, Wei Yang, Hui-Zhi Cai filed Critical Palatin Technologies Inc
Priority to EP07759833.2A priority patent/EP2001518B1/en
Priority to DK07759833.2T priority patent/DK2001518T3/en
Publication of WO2007115175A2 publication Critical patent/WO2007115175A2/en
Priority to IL194262A priority patent/IL194262A/en
Publication of WO2007115175A3 publication Critical patent/WO2007115175A3/en
Priority to HK10101204.8A priority patent/HK1134022A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R', Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti hypertensive, cardiovascular, renal or endocrine effects are desired.
PCT/US2007/065645 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs WO2007115175A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES07759833T ES2430323T3 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
CN200780019541.7A CN101505784B (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
JP2009503312A JP5355383B2 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide construct
EA200802059A EA016804B1 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
AU2007233116A AU2007233116B2 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
KR1020087026715A KR101434612B1 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
CA002647143A CA2647143A1 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
MX2008012663A MX2008012663A (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs.
EP07759833.2A EP2001518B1 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs
DK07759833.2T DK2001518T3 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide preparations
IL194262A IL194262A (en) 2006-03-30 2008-09-22 Cyclic natriuretic peptide constructs
HK10101204.8A HK1134022A1 (en) 2006-03-30 2010-02-04 Cyclic natriuretic peptide constructs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74396006P 2006-03-30 2006-03-30
US74396106P 2006-03-30 2006-03-30
US60/743,960 2006-03-30
US60/743,961 2006-03-30

Publications (2)

Publication Number Publication Date
WO2007115175A2 WO2007115175A2 (en) 2007-10-11
WO2007115175A3 true WO2007115175A3 (en) 2008-12-11

Family

ID=38564246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/065645 WO2007115175A2 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs

Country Status (15)

Country Link
US (2) US7622440B2 (en)
EP (1) EP2001518B1 (en)
JP (1) JP5355383B2 (en)
KR (1) KR101434612B1 (en)
AU (1) AU2007233116B2 (en)
BR (1) BRPI0709427A2 (en)
CA (1) CA2647143A1 (en)
CO (1) CO6140040A2 (en)
DK (1) DK2001518T3 (en)
EA (1) EA016804B1 (en)
ES (1) ES2430323T3 (en)
HK (1) HK1134022A1 (en)
IL (1) IL194262A (en)
MX (1) MX2008012663A (en)
WO (1) WO2007115175A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709405A2 (en) * 2006-03-30 2011-07-12 Palatin Technologies Inc linear or cyclic compounds
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
BRPI0709427A2 (en) * 2006-03-30 2011-07-12 Palatin Technologies Inc "Cyclic construct, pharmaceutical composition and use of a compound
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US7964181B2 (en) 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
CA2647146A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
JP5797191B2 (en) 2009-06-05 2015-10-21 １３セラピューティクス， インコーポレイテッド Immunomodulating peptides and uses thereof
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
KR101854820B1 (en) * 2009-09-25 2018-05-04 샤이어 오펀 테라피즈 게엠베하 Novel NPR-B Agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
EP2560670A4 (en) * 2010-04-21 2014-02-26 Palatin Technologies Inc Uses of natriuretic peptide constructs
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
KR101867026B1 (en) 2011-12-28 2018-07-20 대우조선해양 주식회사 Treatment module of untreated water for ballast water treatment systme
EP3983437A1 (en) 2019-06-12 2022-04-20 Novartis AG Natriuretic peptide receptor 1 antibodies and methods of use

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4496544A (en) 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4952561A (en) 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides
JPS60184098A (en) 1984-03-02 1985-09-19 Suntory Ltd Novel peptide and diuretic comprising it as active ingredient
WO1985004870A1 (en) 1984-04-19 1985-11-07 Biotechnology Research Partners, Ltd. Novel atrial natriuretic/vasodilator polypeptides
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
AU4292785A (en) 1984-04-24 1985-11-15 Salk Institute For Biological Studies, The Atrial peptide analogs
JPH0672155B2 (en) 1984-08-24 1994-09-14 塩野義製薬株式会社 Polypeptide for producing α-hANP antiserum
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
EP0223143A3 (en) * 1985-11-05 1989-04-12 California Biotechnology, Inc. Analogs of atrial natriuretic peptides
DE3614833A1 (en) 1986-01-16 1987-07-23 Hoechst Ag PEPTIDES WITH VASORELAXING, NATRIURETIC AND DIURETIC EFFECTS, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS CONTAINING THEM AND THEIR USE
US5057603A (en) 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
US4716147A (en) 1986-03-27 1987-12-29 Monsanto Company Synthetic airial peptides
EP0246795A3 (en) 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetic natriuretic peptides
US5159061A (en) 1986-09-29 1992-10-27 Takeda Chemical Industries, Ltd. Atrial natriuretic peptide derivative
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
DK531986D0 (en) 1986-11-07 1986-11-07 Novo Industri As PEPTIDES
DE3878231T2 (en) 1987-03-02 1993-05-27 Forssmann Wolf Georg NEW CADIODILATIN FRAGMENT, PROCESS FOR THEIR PRODUCTION AND USE.
US5376635A (en) 1987-03-15 1994-12-27 Bio-Mega/Boehringer Ingelheim Research Inc. Fluorine containing atrial natriuretic peptides
IL85728A (en) 1987-03-25 1993-01-14 Bio Mega Inc Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them
US4816443A (en) 1987-05-19 1989-03-28 Merck & Co., Inc. Piptides having ANF activity
US5091366A (en) 1987-05-19 1992-02-25 Merck & Co., Inc. Peptides having ANF activity
IL86386A0 (en) 1987-05-21 1988-11-15 Merrell Dow Pharma Novel anf derivatives
JP2544929B2 (en) 1987-06-17 1996-10-16 第一化学薬品 株式会社 Novel bioactive peptide
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
WO1989005654A1 (en) 1987-12-24 1989-06-29 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
US5047397A (en) 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
WO1989010935A1 (en) 1988-05-09 1989-11-16 Abbott Laboratories Atrial peptide derivatives
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5057495A (en) 1988-06-24 1991-10-15 Queen's University At Kingston Atrial hypotensive peptide
DK380288D0 (en) 1988-07-07 1988-07-07 Novo Industri As HOW TO UNKNOWN PEPTIDES
AU4211989A (en) 1988-08-18 1990-03-23 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5106834A (en) 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
DK0385476T4 (en) 1989-03-01 1999-12-20 Shionogi & Co Physiologically active polypeptide and DNA
EP0431113A4 (en) 1989-05-24 1992-01-22 Abbott Laboratories Atrial peptide derivatives
JP3394040B2 (en) 1989-06-23 2003-04-07 ジェネンテック・インコーポレーテッド Compositions and methods of synthesis and use of natriuretic protein receptor B
ATE164080T1 (en) 1990-05-10 1998-04-15 Bechgaard Int Res PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETHYLENE GLYCOLS
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
SK32693A3 (en) 1990-10-11 1993-09-09 Boehringer Ingelheim Kg Cyclopeptides, a method of preparing them and their use as drugs
JP2809533B2 (en) 1991-01-31 1998-10-08 壽之 松尾 CNP analog peptide
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JP2925391B2 (en) 1992-01-09 1999-07-28 サントリー株式会社 Pharmaceutical composition for treating ARDS
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
WO1995013296A1 (en) 1993-11-12 1995-05-18 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5567662A (en) 1994-02-15 1996-10-22 The Dow Chemical Company Method of making metallic carbide powders
FR2717484A1 (en) 1994-03-16 1995-09-22 Pf Medicament New pseudo-bis-peptide cpds.
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
PT914344E (en) 1996-03-04 2005-10-31 Scios Inc TEST AND REAGENTS FOR HBNP QUANTIFICATION
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
ES2158611T3 (en) 1996-12-20 2001-09-01 Alza Corp COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION.
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
AU9487698A (en) 1997-09-11 1999-03-29 Music Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
KR100691545B1 (en) 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001016295A1 (en) 1999-09-01 2001-03-08 The Regents Of The University Of California Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003081246A1 (en) 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
WO2003079979A2 (en) 2002-03-18 2003-10-02 Scios Inc. Method for treating congestive heart failure
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
CN102139114A (en) 2003-02-26 2011-08-03 尼克塔治疗公司 Polymer factor VIII moiety conjugates
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
CA2554599A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
CA2576852A1 (en) 2004-08-11 2006-02-23 Alza Corporation Apparatus and method for transdermal delivery of natriuretic peptides
BRPI0709427A2 (en) 2006-03-30 2011-07-12 Palatin Technologies Inc "Cyclic construct, pharmaceutical composition and use of a compound
CA2647146A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE VISSER P.C.J.: "Solid-phase synthesis of polymyxin B1 and analogues via a safety-catch approach", PEPTIDE RES., vol. 61, no. 6, June 2003 (2003-06-01), pages 298 - 306, XP002389978 *
DUTTA A.S., JOURNAL OF PEPTIDE SCIENCE, vol. 6, 2000, pages 321 - 341, XP002564522 *
See also references of EP2001518A4 *

Also Published As

Publication number Publication date
EP2001518A2 (en) 2008-12-17
ES2430323T3 (en) 2013-11-20
BRPI0709427A2 (en) 2011-07-12
JP2009532384A (en) 2009-09-10
WO2007115175A2 (en) 2007-10-11
IL194262A (en) 2014-05-28
CA2647143A1 (en) 2007-10-11
EA016804B1 (en) 2012-07-30
KR101434612B1 (en) 2014-08-26
CO6140040A2 (en) 2010-03-19
AU2007233116A1 (en) 2007-10-11
US20100075895A1 (en) 2010-03-25
US20070265206A1 (en) 2007-11-15
US8580747B2 (en) 2013-11-12
KR20090025196A (en) 2009-03-10
EP2001518B1 (en) 2013-07-10
JP5355383B2 (en) 2013-11-27
EP2001518A4 (en) 2009-11-04
HK1134022A1 (en) 2010-04-16
MX2008012663A (en) 2008-10-13
AU2007233116B2 (en) 2013-05-09
US7622440B2 (en) 2009-11-24
DK2001518T3 (en) 2013-10-07
EA200802059A1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
WO2007115175A3 (en) Cyclic natriuretic peptide constructs
WO2007115182A3 (en) Linear natriuretic peptide constructs
NZ602905A (en) Fgf-r4 receptor-specific antagonists
EP3336182A3 (en) Modified phosphatases
EP3670536A3 (en) Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
WO2009034119A8 (en) Improved derivatives of amylin
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
WO2009065600A3 (en) Means for treating myosin-related diseases
WO2009058662A3 (en) Glucagon antagonists
WO2008093060A3 (en) Peptides and their use
NZ597692A (en) Anti-IGF antibodies
NZ616761A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
DE602005021858D1 (en) PEPTIDES OF THE AMYLIN FAMILY, PROCESS FOR THEIR PREPARATION AND USE
NZ603623A (en) Tcr complex immunotherapeutics
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
WO2007115724A3 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
WO2010028066A3 (en) Cd133 epitopes
NO20092261L (en) Methods for Promoting Heart Repair Using Growth Factors Fused to Heparin Binding Sequences

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780019541.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07759833

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 194262

Country of ref document: IL

Ref document number: 2647143

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007759833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12008502187

Country of ref document: PH

Ref document number: 2009503312

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012663

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2265/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200802059

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007233116

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 08116413

Country of ref document: CO

Ref document number: 1020087026715

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007233116

Country of ref document: AU

Date of ref document: 20070330

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0709427

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080930